|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, March 31, 2012 ) New York, NY -- At the conclusion of each week, VFC's Stock House examines some news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. Although focusing intently on the biotech and healthcare sectors, due attention is also given to potential market-moving or game-changing companies in a broad variety of markets and industries. The 'Weekly Stock Watch' will also introduce new companies for coverage and identify some stocks that may have entered 'buy territory'.
Here's a toast to the first quarter of 2012, one that returned quite a bit of green to the portfolios of many an investor, renewed confidence in the markets and also had many forget the dog days of early 2009 when everybody and their brother was telling you to sell everything.
Those that might have bucked the selling trend and used the dip to buy are sitting pretty right about now, but that doesn't mean another market correction isn't in the works.
For more on the market take visit: http://vfcsstockhouse.com/blog/article/-weekly-news-stock-watch-rimm-fcel-siri-snss-onty-cvm-actc-siga-cndo-ttnp-cpst-bvti-abpi
This week VFC's Stock House takes a look a Research In Motion (RIMM) and its prospects for success, Sirius XM (SIRI) and the possible Liberty majority stake, the pending Advanced Cell Technology (ACTC) reverse split, and Coronoado Biosciences (CNDO) as a potential big player in multiple billion dollar markets.
Investors may be drawn to Coronado for its unique pipeline and market potential. the company has two flagship products in development with multiple tria-based catalysts coming due in 2012.
CNDO-201, is known as TSO (Trichuris suis ova) and is a biologic being developed for the treatment of numerous autoimmune diseases, including Crohn's disease, ulcerative colitis and multiple sclerosis. The biologic treatment itself is actually a porcine whipworm that has proven in early studies to reduce, and sometimes eliminate altogether, the effects of the conditions listed above. Because the whipworm ova being used for treatment have not adapted to reproduction in humans, there is no threat of them multiplying and the safety profile has been sound.
Through the course of 2012 Coronado plans to initiate a Phase IIb Chron's trial in the US (2Q), a Phase II Multiple Sclerosis trial in the US (2H) and a European Phase II Chron's study, in conjunction with licensing partner, Falk.
CNDO-109, or Activated Natural Killer Cells, is being developed for the treatment of acute myeloid leukemia (AML). A Phase I has already been completed and presented for this indication and the company expects to launch a Phase II is mid-2012. Preclinical studies of this technology have also demonstrated success in multiple other cancer types, including breast, prostate and ovarian, leaving open a significant market opportunity, should additional trials prove as successful as the early ones.
Coronado has two solid pipelines moving forward in multi-billion dollar markets that have thus far demonstrated solid results. Generally, the patient investor benefits most by getting into a sound technology early. With multiple catalysts pending this year, and considering that there are no prescription alternatives available for some of the indications being targeted by CNDO-201, Coronado may be presenting a unique investing opportunity.
A full report on Coronado will be available at VFC's Stock House early in the week.
For the full Weekly Stock Watch list visit: http://vfcsstockhouse.com/blog/article/-weekly-news-stock-watch-rimm-fcel-siri-snss-onty-cvm-actc-siga-cndo-ttnp-cpst-bvti-abpi
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFCÂ’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com 
Source: EmailWire.com
|
|
|
|
